Actovegin

Summary

Actovegin (CHEMBL2108885) is a phase-3 clinical-stage unknown; indicated across 2 conditions including diabetic neuropathy and peripheral arterial disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 2 conditions
• Clinical trials: 2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108885
Name	Actovegin
Type	Unknown
Max phase	3

Also known as: Actovegin, ACTOVEGIN

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
diabetic neuropathy	3	MONDO:0006626	EFO:1000783
peripheral arterial disease	3	MONDO:0005386	EFO:0004265

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01582854	PHASE3	COMPLETED	Efficacy and Safety of Actovegin in Post-stroke Cognitive Impairment (PSCI)
NCT03469349	PHASE3	COMPLETED	Actovegin 12-Week Treatment Given First Intravenously and Subsequently Orally in Participants With Peripheral Arterial Occlusive Disease Fontaine Stage IIB

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).